Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
NCT ID: NCT00743379
Last Updated: 2015-05-07
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1/PHASE2
Total Enrollment
71 participants
Study Classification
INTERVENTIONAL
Study Start Date
2008-08-31
Study Completion Date
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate Cancer, and Non-small Cell Lung Cancer, respectively.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
NCT00495144
Tumors
Hypoxia
COMPLETED
PHASE1
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217
Solid Tumor
Hepatocellular Carcinoma
Colorectal Cancer
+3 more
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
TH1902 in Patients With Advanced Solid Tumors
NCT04706962
Solid Tumor
TNBC - Triple-Negative Breast Cancer
Hormone Receptor-positive Breast Cancer
+7 more
ACTIVE_NOT_RECRUITING
PHASE1
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
NCT00977067
Solid Cancers
TERMINATED
PHASE1
Dose Escalation Study of Pazopanib Plus TH-302
NCT01485042
Solid Tumors
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A broad range of tumors have been shown to contain significant numbers of hypoxic cells and hypoxia has been shown to be associated with a poor prognosis and an increase in resistance to chemotherapy and radiotherapy (Brizel 1997, Vaupel 2007, Shannon 2003).
It is likely that an agent that could effectively target hypoxic regions in tumors would improve efficacy when combined with standard chemotherapy or radiotherapy. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies. This should result in an improved therapeutic ratio (tumor vs normal tissue toxicity) as compared with other bioreductive agents. Because TH-302 is expected to be minimally toxic to aerobic cancer cells, optimal efficacy would be expected when TH-302 is combined with treatments that are most effective under aerobic conditions such as radiotherapy and cytotoxic chemotherapy. Preclinical data have shown at least additive efficacy when TH-302 is combined with either docetaxel or gemcitabine. In order to minimize the risk of additive toxicity, TH-302 is not being evaluated in combination with alkylating agents.
It is likely that an agent that could effectively target hypoxic regions in tumors would improve efficacy when combined with standard chemotherapy or radiotherapy. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies. This should result in an improved therapeutic ratio (tumor vs normal tissue toxicity) as compared with other bioreductive agents. Because TH-302 is expected to be minimally toxic to aerobic cancer cells, optimal efficacy would be expected when TH-302 is combined with treatments that are most effective under aerobic conditions such as radiotherapy and cytotoxic chemotherapy. Preclinical data have shown at least additive efficacy when TH-302 is combined with either docetaxel or gemcitabine. In order to minimize the risk of additive toxicity, TH-302 is not being evaluated in combination with alkylating agents.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-Small Cell Lung Cancer
Prostate Cancer
Pancreatic Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Group Type
EXPERIMENTAL
TH-302
Intervention Type
DRUG
TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
B
TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
Group Type
EXPERIMENTAL
TH-302
Intervention Type
DRUG
TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
C
TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
Group Type
EXPERIMENTAL
TH-302
Intervention Type
DRUG
TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TH-302
TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. At least 18 years of age
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form
3. Dose escalation subjects:
a. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR solid malignancy for which monotherapy with gemcitabine is considered standard therapy b. Tumor progression after most recent therapy
Dose expansion subjects:
a. Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided) previously untreated with chemotherapy other than radiosensitizing doses of 5-fluorouracil
4. Recovered from toxicities of prior therapy to grade 0 or 1
5. Evaluable disease by RECIST criteria (at least one target or non-target lesion)
6. ECOG 0 or 1
7. Life expectancy of at least 3 months
8. Acceptable liver function:
a. Bilirubin ≤ 1.5 times upper limit of normal b. AST (SGOT) and ALT (SGPT) ≤ 2.5xULN; if liver metastases are present, then ≤ 5xULN is allowed
9. Acceptable renal function:
a. Serum creatinine ≤ ULN
10. Acceptable hematologic status:
1. ANC ≥ 1500 cells/μL
2. Platelet count ≥ 100,000/μL
3. Hemoglobin ≥ 9.0 g/dL
11. All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner from entry into the study through 6 months after the last dose
All Subjects:
1. At least 18 years of age
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form
3. Dose escalation subjects ONLY:
a. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR solid malignancy for which monotherapy with docetaxel would be appropriate b. Tumor progression after most recent therapy
4. Recovered from toxicities of prior therapy to grade 0 or 1
5. Evaluable disease by RECIST criteria (at least one target or non-target lesion) or evidence of disease progression for subjects with metastatic castrate-resistant prostate cancer
6. ECOG 0 or 1
7. Life expectancy of at least 3 months
8. Acceptable liver function:
a. Bilirubin ≤ upper limit of normal b. AST (SGOT) and ALT (SGPT) ≤ 1.5x ULN with alkaline phosphatase ≤ 2.5x ULN
9. Acceptable renal function:
a. Serum creatinine ≤ ULN
10. Acceptable hematologic status:
1. ANC ≥ 1500 cells/μL
2. Platelet count ≥ 100,000/μL
3. Hemoglobin ≥ 9.0 g/dL
11. All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner from entry into the study through 6 months after the last dose
Expanded Cohort Subjects or dose-escalation subjects with metastatic castrate-resistant prostate cancer previously untreated with chemotherapy:
1. Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of metastatic disease
2. Disease progression during hormone therapy and received primary androgenablation therapy as maintenance
3. For subjects who have not had orchiectomy: serum testosterone concentration \<50 ng/mL (\<1.7 nmol/L); GnRH analog therapy must be continued during this study
4. If there has been antiandrogen withdrawal, it must have occurred at least 4 weeks before study enrollment (6 weeks for bicalutamide) OR in subjects who have had an antiandrogen added as second-line therapy and there was no response to the most recent antiandrogen therapy or if the PSA decline lasted ≤3 months, antiandrogen therapy must be discontinued for at least 2 weeks
5. Evidence of disease progression, manifested by at least one of the following:
1. Rising PSA on at least 3 measurements at least 1 week apart
2. Disease progression on physical examination or imaging studies (if progression is based on bone scan alone, there must be at least 2 new bone lesions)
6. Previously untreated with systemic chemotherapy
7. PSA at least 2 ng/mL
Expanded Cohort Subjects or dose-escalation subjects with second-line NSCLC:
1\. Histological or cytological confirmation of NSCLC with stage IIIB or IV disease not amenable to curative therapy 2. Prior treatment with only one systemic chemotherapy regimen for advanced disease 3. Tumor progression after most recent therapy
All Subjects:
1. At least 18 years of age
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form
3. Dose escalation subjects:
a. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR solid malignancy for which monotherapy with pemetrexed is considered standard therapy b. Tumor progression after most recent therapy
4. Recovered from toxicities of prior therapy
5. Evaluable disease by RECIST criteria (at least one target or non-target lesion)
6. ECOG performance status of 0 or 1
7. Life expectancy of at least 3 months
8. Acceptable liver function:
1. Bilirubin ≤ 1.5x ULN
2. AST (SGOT) and ALT (SGPT) ≤ 2.5x ULN; if liver metastases are present, then ≤ 5x ULN is allowed
9. Acceptable renal function:
a. Serum creatinine ≤ ULN and calculated CrCl ≥ 45 mL/min
10. Acceptable hematologic status:
a. ANC ≥ 1500 cells/μL b. Platelet count ≥ 100,000/μL c. Hemoglobin ≥ 9.0 g/dL
11. All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner from entry into the study through 6 months after the last dose Expanded cohort subjects ONLY: Second-line NSCLC
1\. Histological or cytological confirmation of NSCLC with stage IIIB or IV disease not amenable to curative therapy 2. Prior treatment with only one systemic chemotherapy regimen for advanced disease 3. Tumor progression after most recent therapy
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form
3. Dose escalation subjects:
a. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR solid malignancy for which monotherapy with gemcitabine is considered standard therapy b. Tumor progression after most recent therapy
Dose expansion subjects:
a. Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided) previously untreated with chemotherapy other than radiosensitizing doses of 5-fluorouracil
4. Recovered from toxicities of prior therapy to grade 0 or 1
5. Evaluable disease by RECIST criteria (at least one target or non-target lesion)
6. ECOG 0 or 1
7. Life expectancy of at least 3 months
8. Acceptable liver function:
a. Bilirubin ≤ 1.5 times upper limit of normal b. AST (SGOT) and ALT (SGPT) ≤ 2.5xULN; if liver metastases are present, then ≤ 5xULN is allowed
9. Acceptable renal function:
a. Serum creatinine ≤ ULN
10. Acceptable hematologic status:
1. ANC ≥ 1500 cells/μL
2. Platelet count ≥ 100,000/μL
3. Hemoglobin ≥ 9.0 g/dL
11. All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner from entry into the study through 6 months after the last dose
All Subjects:
1. At least 18 years of age
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form
3. Dose escalation subjects ONLY:
a. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR solid malignancy for which monotherapy with docetaxel would be appropriate b. Tumor progression after most recent therapy
4. Recovered from toxicities of prior therapy to grade 0 or 1
5. Evaluable disease by RECIST criteria (at least one target or non-target lesion) or evidence of disease progression for subjects with metastatic castrate-resistant prostate cancer
6. ECOG 0 or 1
7. Life expectancy of at least 3 months
8. Acceptable liver function:
a. Bilirubin ≤ upper limit of normal b. AST (SGOT) and ALT (SGPT) ≤ 1.5x ULN with alkaline phosphatase ≤ 2.5x ULN
9. Acceptable renal function:
a. Serum creatinine ≤ ULN
10. Acceptable hematologic status:
1. ANC ≥ 1500 cells/μL
2. Platelet count ≥ 100,000/μL
3. Hemoglobin ≥ 9.0 g/dL
11. All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner from entry into the study through 6 months after the last dose
Expanded Cohort Subjects or dose-escalation subjects with metastatic castrate-resistant prostate cancer previously untreated with chemotherapy:
1. Histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of metastatic disease
2. Disease progression during hormone therapy and received primary androgenablation therapy as maintenance
3. For subjects who have not had orchiectomy: serum testosterone concentration \<50 ng/mL (\<1.7 nmol/L); GnRH analog therapy must be continued during this study
4. If there has been antiandrogen withdrawal, it must have occurred at least 4 weeks before study enrollment (6 weeks for bicalutamide) OR in subjects who have had an antiandrogen added as second-line therapy and there was no response to the most recent antiandrogen therapy or if the PSA decline lasted ≤3 months, antiandrogen therapy must be discontinued for at least 2 weeks
5. Evidence of disease progression, manifested by at least one of the following:
1. Rising PSA on at least 3 measurements at least 1 week apart
2. Disease progression on physical examination or imaging studies (if progression is based on bone scan alone, there must be at least 2 new bone lesions)
6. Previously untreated with systemic chemotherapy
7. PSA at least 2 ng/mL
Expanded Cohort Subjects or dose-escalation subjects with second-line NSCLC:
1\. Histological or cytological confirmation of NSCLC with stage IIIB or IV disease not amenable to curative therapy 2. Prior treatment with only one systemic chemotherapy regimen for advanced disease 3. Tumor progression after most recent therapy
All Subjects:
1. At least 18 years of age
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form
3. Dose escalation subjects:
a. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR solid malignancy for which monotherapy with pemetrexed is considered standard therapy b. Tumor progression after most recent therapy
4. Recovered from toxicities of prior therapy
5. Evaluable disease by RECIST criteria (at least one target or non-target lesion)
6. ECOG performance status of 0 or 1
7. Life expectancy of at least 3 months
8. Acceptable liver function:
1. Bilirubin ≤ 1.5x ULN
2. AST (SGOT) and ALT (SGPT) ≤ 2.5x ULN; if liver metastases are present, then ≤ 5x ULN is allowed
9. Acceptable renal function:
a. Serum creatinine ≤ ULN and calculated CrCl ≥ 45 mL/min
10. Acceptable hematologic status:
a. ANC ≥ 1500 cells/μL b. Platelet count ≥ 100,000/μL c. Hemoglobin ≥ 9.0 g/dL
11. All women of childbearing potential must have a negative serum pregnancy test and women and men subjects must agree to use effective means of contraception with their partner from entry into the study through 6 months after the last dose Expanded cohort subjects ONLY: Second-line NSCLC
1\. Histological or cytological confirmation of NSCLC with stage IIIB or IV disease not amenable to curative therapy 2. Prior treatment with only one systemic chemotherapy regimen for advanced disease 3. Tumor progression after most recent therapy
Exclusion Criteria
All Subjects:
1. Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
2. Prior treatment with gemcitabine
3. Prior radiotherapy to more than 25% of the bone marrow
4. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
5. Seizure disorders requiring anticonvulsant therapy
6. Symptomatic brain, leptomeningeal or epidural metastases, (unless previously treated and well controlled for a period of ≥ 3 months)
7. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
8. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
9. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
11. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 4 weeks prior to study entry
12. Prior therapy with an hypoxic cytotoxin
13. Subjects who participated in an investigational drug or device study within 28 days prior to study entry
14. Known infection with HIV, hepatitis B or C
15. Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH-302
16. Females who are pregnant or breast-feeding
17. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
18. Unwillingness or inability to comply with the study protocol for any reason Expanded cohort subjects ONLY: First-line advanced adenocarcinoma of the pancreas
1\. Prior chemotherapy therapy for advanced disease other than radiosensitizing doses of 5-fluorouracil
All Subjects:
1. Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
2. Prior treatment with docetaxel
3. Prior radiotherapy to more than 25% of the bone marrow unless radiotherapy was completed \>5 years ago and there is not hematologic evidence of persistent bone marrow suppression
4. Uncontrolled pleural effusion or ascites
5. History of sensitivity to drugs formulated with polysorbate 80
6. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
7. Seizure disorders requiring anticonvulsant therapy
8. Symptomatic brain, leptomeningeal or epidural metastases (unless previously treated and well controlled for a period of ≥ 3 months)
9. Ongoing CTCAE grade 2 or greater peripheral neuropathy
10. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
11. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
12. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
13. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
14. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 4 weeks prior to study entry
15. Prior therapy with an hypoxic cytotoxin
16. Subjects who participated in an investigational drug or device study within 28 days prior to study entry
17. Known active infection with HIV, hepatitis B or C
18. Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH-302
19. Females who are pregnant or breast-feeding
20. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
21. Unwillingness or inability to comply with the study protocol for any reason Expanded Cohort Subjects ONLY: Castrate-resistant prostate cancer
1\. Prior treatment with cytotoxic chemotherapy or radioisotope therapy Expanded Cohort Subjects ONLY: Second-line NSCLC
1. More than one prior cytotoxic chemotherapy regimen for advanced disease
2. Weight loss of \>10% body weight in the previous 6 weeks
All Subjects:
1. Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
2. Prior treatment with pemetrexed
3. Prior radiotherapy to more than 25% of the bone marrow
4. Inability to discontinue non-steroidal anti-inflammatory drugs for 5 days (long half-life) or 2 days (short half-life, if subject has CrCl \<80 mL/min) before until 2 days following pemetrexed dosing
5. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
6. Seizure disorders requiring anticonvulsant therapy
7. Symptomatic brain, leptomeningeal or epidural metastases (unless previously treated and well controlled for a period of ≥ 3 months)
8. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
9. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
10. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
11. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
12. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 4 weeks prior to study entry
13. Prior therapy with an hypoxic cytotoxin
14. Subjects who participated in an investigational drug or device study within 28 days prior to study entry
15. Known active infection with HIV, hepatitis B, or hepatitis C
16. Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH-302
17. Females who are pregnant or breast-feeding
18. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
19. Unwillingness or inability to comply with the study protocol for any reason Expanded Cohort Subjects ONLY: Second-line NSCLC
1\. More than one prior cytotoxic chemotherapy regimen for advanced disease 2. Weight loss of \>10% body weight in the previous 6 weeks
1. Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
2. Prior treatment with gemcitabine
3. Prior radiotherapy to more than 25% of the bone marrow
4. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
5. Seizure disorders requiring anticonvulsant therapy
6. Symptomatic brain, leptomeningeal or epidural metastases, (unless previously treated and well controlled for a period of ≥ 3 months)
7. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
8. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
9. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
11. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 4 weeks prior to study entry
12. Prior therapy with an hypoxic cytotoxin
13. Subjects who participated in an investigational drug or device study within 28 days prior to study entry
14. Known infection with HIV, hepatitis B or C
15. Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH-302
16. Females who are pregnant or breast-feeding
17. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
18. Unwillingness or inability to comply with the study protocol for any reason Expanded cohort subjects ONLY: First-line advanced adenocarcinoma of the pancreas
1\. Prior chemotherapy therapy for advanced disease other than radiosensitizing doses of 5-fluorouracil
All Subjects:
1. Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
2. Prior treatment with docetaxel
3. Prior radiotherapy to more than 25% of the bone marrow unless radiotherapy was completed \>5 years ago and there is not hematologic evidence of persistent bone marrow suppression
4. Uncontrolled pleural effusion or ascites
5. History of sensitivity to drugs formulated with polysorbate 80
6. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
7. Seizure disorders requiring anticonvulsant therapy
8. Symptomatic brain, leptomeningeal or epidural metastases (unless previously treated and well controlled for a period of ≥ 3 months)
9. Ongoing CTCAE grade 2 or greater peripheral neuropathy
10. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
11. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
12. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
13. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
14. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 4 weeks prior to study entry
15. Prior therapy with an hypoxic cytotoxin
16. Subjects who participated in an investigational drug or device study within 28 days prior to study entry
17. Known active infection with HIV, hepatitis B or C
18. Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH-302
19. Females who are pregnant or breast-feeding
20. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
21. Unwillingness or inability to comply with the study protocol for any reason Expanded Cohort Subjects ONLY: Castrate-resistant prostate cancer
1\. Prior treatment with cytotoxic chemotherapy or radioisotope therapy Expanded Cohort Subjects ONLY: Second-line NSCLC
1. More than one prior cytotoxic chemotherapy regimen for advanced disease
2. Weight loss of \>10% body weight in the previous 6 weeks
All Subjects:
1. Prior treatment with more than 3 myelosuppressive cytotoxic chemotherapy regimens
2. Prior treatment with pemetrexed
3. Prior radiotherapy to more than 25% of the bone marrow
4. Inability to discontinue non-steroidal anti-inflammatory drugs for 5 days (long half-life) or 2 days (short half-life, if subject has CrCl \<80 mL/min) before until 2 days following pemetrexed dosing
5. New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic peripheral arterial vascular disease
6. Seizure disorders requiring anticonvulsant therapy
7. Symptomatic brain, leptomeningeal or epidural metastases (unless previously treated and well controlled for a period of ≥ 3 months)
8. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years
9. Severe chronic obstructive or other pulmonary disease with hypoxemia (requires supplementary oxygen, symptoms due to hypoxemia or oxygen saturation \<90% by pulse oximetry after a 2 minute walk) or in the opinion of the investigator any physiological state likely to cause systemic or regional hypoxemia
10. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
11. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
12. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 4 weeks prior to study entry
13. Prior therapy with an hypoxic cytotoxin
14. Subjects who participated in an investigational drug or device study within 28 days prior to study entry
15. Known active infection with HIV, hepatitis B, or hepatitis C
16. Subjects who have exhibited allergic reactions to a structural compound, biological agent, or formulation (containing solutol and/or propylene glycol) similar to TH-302
17. Females who are pregnant or breast-feeding
18. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
19. Unwillingness or inability to comply with the study protocol for any reason Expanded Cohort Subjects ONLY: Second-line NSCLC
1\. More than one prior cytotoxic chemotherapy regimen for advanced disease 2. Weight loss of \>10% body weight in the previous 6 weeks
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Threshold Pharmaceuticals
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey R Infante, MD
Role: PRINCIPAL_INVESTIGATOR
SCRI Development Innovations, LLC
Mitesh Borad, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Cancer Center
Scottsdale, Arizona, United States
Site Status
Premiere Oncology of Arizona
Scottsdale, Arizona, United States
Site Status
Indiana University Cancer Center
Indianapolis, Indiana, United States
Site Status
LSU Health Sciences Center
Shreveport, Louisiana, United States
Site Status
Karmanos Cancer Institute
Detroit, Michigan, United States
Site Status
Mayo Clinic
Rochester, Minnesota, United States
Site Status
Duke University Medical Center
Durham, North Carolina, United States
Site Status
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Site Status
UT Health Science Center
San Antonio, Texas, United States
Site Status
Northwest Medical Specialties
Tacoma, Washington, United States
Site Status
University of Wisconsin
Madison, Wisconsin, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol. 2015 May 1;33(13):1475-81. doi: 10.1200/JCO.2014.55.7504. Epub 2014 Dec 15.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
http://www.thresholdpharm.com
Threshold Pharmaceuticals Company Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TH-CR-402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
NCT00820560
COMPLETED
PHASE1
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587
RECRUITING
PHASE1
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
NCT04774952
COMPLETED
PHASE1
TTP607 in Refractory Solid Malignancies
NCT00939172
WITHDRAWN
PHASE1
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
NCT02020226
UNKNOWN
PHASE1
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
NCT05639751
COMPLETED
PHASE1
Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors
NCT00259818
COMPLETED
PHASE1
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
NCT00876109
COMPLETED
PHASE1
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
NCT03811652
COMPLETED
PHASE1
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
NCT05037149
ACTIVE_NOT_RECRUITING
PHASE1
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
NCT03355066
TERMINATED
PHASE1
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
NCT05309187
COMPLETED
PHASE1
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
NCT01447225
COMPLETED
PHASE1
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
NCT00502567
COMPLETED
PHASE1
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951
RECRUITING
PHASE1
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04250155
ACTIVE_NOT_RECRUITING
PHASE1
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
NCT01001221
TERMINATED
PHASE1/PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
NCT05084859
TERMINATED
PHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
NCT02266745
ACTIVE_NOT_RECRUITING
PHASE2
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
NCT02025803
COMPLETED
PHASE1
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655
RECRUITING
PHASE1/PHASE2
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
NCT07086768
NOT_YET_RECRUITING
PHASE1
A Study of IMP4297 in Patients With Advanced Solid Tumors
NCT03508011
COMPLETED
PHASE1